ViralClear™

Merimepodib a host-directed antiviral for the treatment of COVID-19

July 2020

Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that ViralClear Pharmaceuticals, Inc. ('ViralClear') expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, development and approvals of new products, market acceptance, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on ViralClear's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond ViralClear's control.

These risks and uncertainties, but are not limited to, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; ViralClear's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to ViralClear's products.

ViralClear does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, ViralClear undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contents

ViralClear™

Vision

ViralClear aspires to make the world a safer place by developing a therapeutic platform to address existing and emerging pathogenic threats so that people can engage in everyday life normally and safely

Who are we?

- Formed March 2020 in response to COVID-19 pandemic
- BioSig (NASDAQ BSGM) Subsidiary March 24th
- Raised $12M May 2020
- Lead molecule merimepodib (MMPD; VX-497)
- IND submitted April 23rd; study allowed to proceed May 15th
- First Phase 2 trial initiated June 2020 in combination with remdesivir
- Virtual company with 20 employees and consultants supported by BioSig

ViralClear

ViralClear™

COVID-19 pandemic

COVID-19: A Global Issue

COVID-19

The Biggest Global Health and Economic Crisis of Our Lifetimes

	Confirmed Cases	Deaths
Worldwide	>29.1M*	>925K*
USA	>6.5M*	>194K*

- There is no approved medical treatment yet that cures or prevents COVID-19
- So the disease progresses on with devastating health, human and economic consequences

*Johns Hopkins COVID-19 Dashboard September 14, 2020

Seeking to establish MMPD as the platform antiviral in the treatment of COVID-19

We believe MMPD has the potential to be used by a broad prescriber base across multiple settings

ViralClear

Hospitals

Clinics

Primary Care Physicians

Therefore, upon regulatory approval, MMPD would need a breadth of commercial support

There may not be a single silver bullet solution for COVID-19
We believe that we must focus on a multi-faceted approach…not just vaccines

ViralClear™

Approaches include, but are not limited to:

Direct Treatments

- **Antivirals** for inhibition of viral replication
- **Immune Modulators** to control inflammatory response and cytokine storm

Prevention

- **Vaccines**

Durability of vaccines may be questionable

CNBC

Dr. Anthony Fauci: “When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that’s protective ranges from 3 to 6 months to almost always less than a year. That’s not a lot of durability and protection.”

Urgent Need for Effective Direct Treatments

Goals for treating pathogenic viral threats including COVID-19

- ✓Stop disease progression
- ✓Hasten healing
- ✓Accelerate viral clearance
- ✓Stop viral shedding
- ✓Prevention of infection
  - ✓Vaccines
  - ✓Prophylaxis

Merimepodib (MMPD) VX-497

Oral IMPDH inhibitor initially developed by Vertex Pharmaceuticals Inc.

- Deprives replicating virus guanosine, essential for nucleic acid synthesis
- In vitro antiviral activity for RNA and DNA viruses
- A lead development asset for chronic hepatitis C before shelving

Drug licensed to

- Trek Therapeutics, PBC, 2016
- ViralClear Pharmaceuticals Inc., 2020

Chemistry, Manufacturing and Controls (CMC)

- Drug substance [active pharmaceutical ingredient (API)] process developed to be commercially ready for different indications
- MMPD Oral Solution formulation to conduct Phase 2 trials and pivotal trial

Clinical

- 7 Phase 1 studies for different indications – 122 health volunteers/patients exposed to MMPD
- 5 Phase 2 studies for different indications – 339 patients exposed to MMPD
  - 4 chronic hepatitis C studies and I psoriasis study
  - 248 chronic hepatitis C patients treated for 6 months or more

ViralClear™

Preclinical data in SARS-CoV-2

MMPD reduced SARS-CoV-2 viral titers in a Vero Cell culture model

MMPD pre-treated Vero Cells (either 4 hours or overnight [O/n]) were infected with SARS-CoV-2.



Bukreyeva N, Mantlo EK, Sattler RA, Huang C, Paessler S, Zeldis J. The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. bioRxiv doi:
https://doi.org/10.1101/2020.04.07.028589

ViralClear™

In vitro, merimepodib and remdesivir in combination reduce production of infectious SARS-CoV-2 to undetectable levels

Co-treatment with MMPD + REM at concentrations as low as 2.5µM + 1.25µM reduces new production of infectious SARS-CoV-2 to undetectable levels



Co-treatment with equimolar concentrations of MMPD + REM at either 2.5µM or 5µM reduces new production of infectious SARS-CoV-2 to undetectable levels



Available under peer review https://f1000research.com/articles/9-361/v1

ViralClear™

ViralClear™

Merimepodib Development Strategy

Planned Development Strategy (Next 6 Months)

- ✓ Current COVID-19 Phase 2 trials
  - Hospitalized patients as combination with remdesivir
    - 1:1 randomization to merimepodib or placebo
    - 40 subjects -Enrolling
  - Hospitalized patients as monotherapy
    - 1:1 randomization to merimepodib or placebo
    - 40 subjects -Initiating
- ✓ All current clinical research with MMPD Oral Solution; other formulations being developed
- Create path for
  - Emergency Use Authorization/NDA filing
- Initiate pivotal trial
- Initiate outpatient COVID-19 trials

ViralClear

Planned Longer Term Development (> 6 months)

- Study merimepodib's role in all stages of COVID-19
- Explore Viral Diseases of Interest and Emerging Infections
  - Dengue
  - Hemorrhagic Fever
  - Other coronavirus diseases (MERS, SARS)

ViralClear

CMC Objectives

- ✓ Onboard multiple API suppliers for NDA registration batches and commercial launch
- ✓ Identify drug product manufacturer for NDA registration batches and commercial launch
- ✓ Start the NDA filing planning process, including requesting an End Of Phase 2 CMC meeting with FDA

ViralClear

Summary Focus and Speed

ViralClear™

- Quickly repositioned merimepodib for COVID-19 and raised supporting capital
- Established an accomplished Development and Management team
- Top-line data on Phase 2 trials anticipated in 3Q20
- Initiate pivotal trial planned for 4Q20
- File NDA 2Q2021